CAR-T cells and BiTEs in solid tumors: challenges and perspectives

被引：71

作者：

Edeline, Julien ^{[1
]}

Houot, Roch ^{[2
]}

Marabelle, Aurelien ^{[3
]}

Alcantara, Marion ^{[4
]}

机构：

[1] Univ Rennes 1, Ctr Eugene Marquis, Med Oncol, Rennes, France

[2] Univ Rennes, CHU Rennes, INSERM, U1236,Dept Hematol, Rennes, France

[3] Univ Paris Saclay, Dept Innovat Therapeut & Essais Precoces DITEP, INSERM, U1015,CIC1428, Gustave Roussy, France

[4] PSL Res Univ, Inst Curie, Ctr Canc Immunotherapy, INSERM,U932, Paris, France

来源：

JOURNAL OF HEMATOLOGY & ONCOLOGY | 2021年 / 14卷 / 01期

关键词：

CAR-T cells; BiTEs; Bispecific antibodies; Solid tumors; CHIMERIC ANTIGEN RECEPTORS; PHASE-I; INFILTRATING LYMPHOCYTES; CARCINOEMBRYONIC ANTIGEN; ADOPTIVE TRANSFER; ON-TARGET; THERAPY; SAFETY; IMMUNOTHERAPY; EFFICACY;

D O I：

10.1186/s13045-021-01067-5

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Chimeric antigen receptor (CAR)-modified T cells and BiTEs are both immunotherapies which redirect T cell specificity against a tumor-specific antigen through the use of antibody fragments. They demonstrated remarkable efficacy in B cell hematologic malignancies, thus paving the way for their development in solid tumors. Nonetheless, the use of such new drugs to treat solid tumors is not straightforward. So far, the results from early phase clinical trials are not as impressive as expected but many improvements are under way. In this review we present an overview of the clinical development of CAR-T cells and BiTEs targeting the main antigens expressed by solid tumors. We emphasize the most frequent hurdles encountered by either CAR-T cells or BiTEs, or both, and summarize the strategies that have been proposed to overcome these obstacles.

引用

页数：12

共 110 条

[1]

Adusumilli PS, 2019, ASCO ANN M AM SOC CL

[2] Human Epidermal Growth Factor Receptor 2 (HER2) -Specific Chimeric Antigen Receptor-Modified T Cells for the Immunotherapy of HER2-Positive Sarcoma [J].

Ahmed, Nabil ;

Brawley, Vita S. ;

Hegde, Meenakshi ;

Robertson, Catherine ;

Ghazi, Alexia ;

Gerken, Claudia ;

Liu, Enli ;

Dakhova, Olga ;

Ashoori, Aidin ;

Corder, Amanda ;

Gray, Tara ;

Wu, Meng-Fen ;

Liu, Hao ;

Hicks, John ;

Rainusso, Nino ;

Dotti, Gianpietro ;

Mei, Zhuyong ;

Grilley, Bambi ;

Gee, Adrian ;

Rooney, Cliona M. ;

Brenner, Malcolm K. ;

Heslop, Helen E. ;

Wels, Winfried S. ;

Wang, Lisa L. ;

Anderson, Peter ;

Gottschalk, Stephen .

JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (15) :1688-+

[3]

Amrolia PJ., 2019, PHASE STUDY AUTO3 BI, DOI [10.1182/blood-2019-123424, DOI 10.1182/BLOOD-2019-123424]

[4] TriTACs, a Novel Class of T-Cell-Engaging Protein Constructs Designed for the Treatment of Solid Tumors [J].

Austin, Richard J. ;

Lemon, Bryan D. ;

Aaron, Wade H. ;

Barath, Manasi ;

Culp, Patricia A. ;

DuBridge, Robert B. ;

Evnin, Luke B. ;

Jones, Adrie ;

Panchal, Anand ;

Patnaik, Purbasa ;

Ramakrishnan, Vanitha ;

Rocha, Sony S. ;

Seto, Pui ;

Sexton, Kenneth ;

Strobel, Kathryn L. ;

Wall, Russell ;

Yu, Stephen ;

Yu, Timothy Z. ;

Law, Che-Leung ;

Baeuerle, Patrick A. ;

Wesche, Holger .

MOLECULAR CANCER THERAPEUTICS, 2021, 20 (01) :109-120

[5] Preclinical evaluation of BiTE®immune therapy targeting MUC17 or CLDN18.2 for gastric cancer [J].

Bailis, Julie M. ;

Lutterbuese, Petra ;

Thomas, Oliver ;

Locher, Kathrin ;

Harrold, John ;

Boyle, Michael ;

Wahl, Joachim ;

Li, Shyun ;

Sternjak, Alexander ;

Henn, Anja ;

Dahlhoff, Christoph ;

Naegele, Virginie ;

Rattel, Benno ;

Raum, Tobias ;

Coxon, Angela .

CANCER RESEARCH, 2020, 80 (16)

[6] Activity of Mesothelin-Specific Chimeric Antigen Receptor T Cells Against Pancreatic Carcinoma Metastases in a Phase 1 Trial [J].

Beatty, Gregory L. ;

O'Hara, Mark H. ;

Lacey, Simon F. ;

Torigian, Drew A. ;

Nazimuddin, Farzana ;

Chen, Fang ;

Kulikovskaya, Irina M. ;

Soulen, Michael C. ;

McGarvey, Maureen ;

Nelson, Anne Marie ;

Gladney, Whitney L. ;

Levine, Bruce L. ;

Melenhorst, J. Joseph ;

Plesa, Gabriela ;

June, Carl H. .

GASTROENTEROLOGY, 2018, 155 (01) :29-32

[7] Treatment of hepatocellular carcinoma with a GPC3-targeted bispecific T cell engager [J].

Bi, Yanyu ;

Jiang, Hua ;

Wang, Peng ;

Song, Bo ;

Wang, Huamao ;

Kong, Xianming ;

Li, Zonghai .

ONCOTARGET, 2017, 8 (32) :52866-52876

[8] Trivalent CAR T cells overcome interpatient antigenic variability in glioblastoma [J].

Bielamowicz, Kevin ;

Fousek, Kristen ;

Byrd, Tiara T. ;

Samaha, Hebatalla ;

Mukherjee, Malini ;

Aware, Nikita ;

Wu, Meng-Fen ;

Orange, Jordan S. ;

Sumazin, Pavel ;

Man, Tsz-Kwong ;

Joseph, Sujith K. ;

Hegde, Meenakshi ;

Ahmed, Nabil .

NEURO-ONCOLOGY, 2018, 20 (04) :506-518

[9] Induction of a central memory and stem cell memory phenotype in functionally active CD4+ and CD8+ CAR T cells produced in an automated good manufacturing practice system for the treatment of CD19+ acute lymphoblastic leukemia [J].

Blaeschke, Franziska ;

Stenger, Dana ;

Kaeuferle, Theresa ;

Willier, Semjon ;

Lotfi, Ramin ;

Kaiser, Andrew Didier ;

Assenmacher, Mario ;

Doering, Michaela ;

Feucht, Judith ;

Feuchtinger, Tobias .

CANCER IMMUNOLOGY IMMUNOTHERAPY, 2018, 67 (07) :1053-1066

[10] Resistance to anti-CD19/CD3 BiTE in acute lymphoblastic leukemia may be mediated by disrupted CD19 membrane trafficking [J].

Braig, Friederike ;

Brandt, Anna ;

Goebeler, Mariele ;

Tony, Hans-Peter ;

Kurze, Anna-Katharina ;

Nollau, Peter ;

Bumm, Thomas ;

Boettcher, Sebastian ;

Bargou, Ralf C. ;

Binder, Mascha .

BLOOD, 2017, 129 (01) :100-104

← 1 2 3 4 5 6 7 8 9 10 →